VIRO Stock Overview
ViroGates A/S, an in vitro diagnostics company, develops and markets prognostic products for the healthcare sector.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
ViroGates A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr.6.88 |
| 52 Week High | kr.25.30 |
| 52 Week Low | kr.4.98 |
| Beta | 0.89 |
| 1 Month Change | 9.90% |
| 3 Month Change | -15.69% |
| 1 Year Change | -67.08% |
| 3 Year Change | -95.94% |
| 5 Year Change | -85.14% |
| Change since IPO | -91.95% |
Recent News & Updates
Recent updates
ViroGates (CPH:VIRO) Is In A Good Position To Deliver On Growth Plans
Mar 06
We're Hopeful That ViroGates (CPH:VIRO) Will Use Its Cash Wisely
Nov 21Will ViroGates (CPH:VIRO) Spend Its Cash Wisely?
Jun 14We're Not Very Worried About ViroGates' (CPH:VIRO) Cash Burn Rate
Sep 19We Think ViroGates (CPH:VIRO) Can Afford To Drive Business Growth
Apr 14We Think ViroGates (CPH:VIRO) Can Afford To Drive Business Growth
Dec 30
Shareholder Returns
| VIRO | DK Medical Equipment | DK Market | |
|---|---|---|---|
| 7D | 9.9% | 2.3% | 0.9% |
| 1Y | -67.1% | 0.3% | 26.5% |
Price Volatility
| VIRO volatility | |
|---|---|
| VIRO Average Weekly Movement | 11.4% |
| Medical Equipment Industry Average Movement | 5.7% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in DK Market | 9.4% |
| 10% least volatile stocks in DK Market | 3.0% |
Volatility Over Time: VIRO's weekly volatility has decreased from 19% to 11% over the past year, but is still higher than 75% of Danish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 10 | Jakob Knudsen | www.virogates.com |
ViroGates A/S, an in vitro diagnostics company, develops and markets prognostic products for the healthcare sector. It offers suPARnostic, a proprietary biomarker used in hospital emergency services to support the clinical decision on hospitalization or discharge of acute patients and to identify high-risk sepsis patients at an early stage, as well as used for the prognosis of lifestyle-related diseases, such as cardiovascular disease, type 2 diabetes, and cancer; and for the assessment of longevity and biological age in a non-hospital setting. The company’ products icludes suPARnostic TurbiLatex, a latex particle-enhanced turbidimetric immunoassay that quantitatively determines the soluble urokinase plasminogen activator receptor (suPAR) level in human K2-EDTA- or lithium heparin plasma samples; suPARnostic ELISA that provides fully quantitative results; suPARnostic Quick Triage kit, which is used in the point of care situation for early warning and patient triaging that will allow clinicians and nurses to obtain a fast patient prognosis for patient disease severity, progression and outcome; and suPARnostic POC+, a point-of-care finger prick test that detects the level of suPAR in the blood.
ViroGates A/S Fundamentals Summary
| VIRO fundamental statistics | |
|---|---|
| Market cap | kr.44.34m |
| Earnings (TTM) | -kr.12.10m |
| Revenue (TTM) | kr.6.99m |
6.3x
P/S Ratio-3.7x
P/E RatioIs VIRO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VIRO income statement (TTM) | |
|---|---|
| Revenue | kr.6.99m |
| Cost of Revenue | kr.1.18m |
| Gross Profit | kr.5.81m |
| Other Expenses | kr.17.90m |
| Earnings | -kr.12.10m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 02, 2024
| Earnings per share (EPS) | -1.88 |
| Gross Margin | 83.08% |
| Net Profit Margin | -173.12% |
| Debt/Equity Ratio | 31.2% |
How did VIRO perform over the long term?
See historical performance and comparison